<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Характеристика взаимодействия специфических антител с Pgp в клетках Т-лимфобластного лейкоза линии Jurkat</article-title><trans-title-group xml:lang="en"><trans-title>Parameters of Specific Antibody Interaction with Pgp in T-Cell Leukemia Jurkat Cells</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богуш</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogush</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudko</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богуш</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogush</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барышников</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Baryshnikov</surname><given-names>A. YU.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский онкологический научный центр им. Н.Н. Блохина РАМН, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian N.N. Blokhin Memorial Cancer Research Center Russian Academy of Medical Sciences, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>05</month><year>2020</year></pub-date><volume>54</volume><issue>1-2</issue><fpage>3</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богуш Т.А., Дудко Е.А., Богуш Е.А., Барышников А.Ю., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Богуш Т.А., Дудко Е.А., Богуш Е.А., Барышников А.Ю.</copyright-holder><copyright-holder xml:lang="en">Bogush T.A., Dudko E.A., Bogush E.A., Baryshnikov A.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/196">https://www.antibiotics-chemotherapy.ru/jour/article/view/196</self-uri><abstract><p>Изучены методические особенности оценки экспрессии Pgp методом проточной цигофлуориметрии. В культуре клеток Т-лимфобластного лейкоза человека линии Jurkat проанализирован характер взаимодействия моноклональных (клон17F9) антител Becton Dickinson Pharmingen к внешнему эпитопу Pgp, меченных FITC, в зависимости от концентрации исследуемых клеток (от 400 тыс. до 3 млн клеток в мл) и концентрации специфических антител (5, 10 и 20 мкл раствора коммерческого препарата на 300 мкл клеточной суспензии). Результаты. 1. Оптимальное условие инкубации с антителами - после фиксации клеток 4% раствором формальдегида. 2. Характер увеличения средней интенсивности флуоресценции клеток совокупно по всей суспензии при увеличении концентрации специфических антител не зависит от количества клеток. 3. Абсолютные значения средней интенсивности специфической флуоресценции клеток и количество клеток за областью флуоресценции изотипического контроля зависят от соотношения количество клеток/концентрация моноклональных антител. Заключение. 1. Pgp экспрессирован практически во всех клетках Jurkat. 2. По уровню экспрессии Pgp культура клеток Jurkat достаточно однородна и стабильна в разных пассажах. 3. Клетки Jurkat могут быть использованы в качестве тест-культуры при оценке активности коммерческих антител. 4. При иммунофлуоресцентном анализе экспрессии Pgp в биопсийном материале опухолей человека необходимо использовать не менее трех концентраций специфических антител, не менее трех концентраций клеток в исследуемой суспензии с обязательным параллельным исследованием охарактеризованной клеточной тест-системы (в частности, для изученных моноклональных антител - культуру клеток линии Jurkat). Это позволит не только констатировать факт, но и выраженность экспрессии Pgp, то есть диагностировать тяжесть фенотипа множественной лекарственной резистентности.</p></abstract><trans-abstract xml:lang="en"><p>Special features of Pgp expression evaluation by flow cytometry were investigated. Indexes of interaction of FITC-conjugated Becton Dickinson Pharmingen monoclonal antibodies to external Pgp epitope (clone 17F9) were analyzed depending on the cell concentration (400000 to 3000000 cells/ml) and the specific antibody concentration (5, 10 and 20 μl of the market product solution per 300 μl of the cell suspension). Results. 1. Optimal condition of incubation with the antibodies was revealed - after the cell fixation in 4% formaldehyde. 2. Character of the increase of the cell fluorescence average intensity in the suspension totally according to the concentration of the Pgp-specific antibodies did not depend on the number of the cells. 3. Both the absolute value of the average intensity of the cell specific fluorescence as well as cell number out of the isotypic control fluorescence region depended on the ratio of the cell number to monoclonal antibody concentration. Conclusion. 1. It was shown that Pgp was practically expressed in all Jurkat cells. 2. By the Pgp expression level, the Jurkat cell culture was sufficiently homogeneous and stable in various passages. 3. Jurkat cells could be used as test culture in estimation of the market antibody activity. 4. For immunofluorescent assay of the Pgp expression in human tumor biopsy specimens, it is necessary to use not less than three concentrations of the specific antibodies, not less than three concentrations of the cells in the suspension as well as concurrent assay of the cell culture characterized previously. In particular, for investigated Pgp monoclonal antibodies, it is possible to use Jurkat cell culture. It allows revealing not only the fact of the Pgp expression but the level of the expression as well, i. e. to estimate severity of multidrug resistance phenotype.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>линия клеток Т-лимфобластного лейкоза Jurkat</kwd><kwd>антитела к Pgp</kwd><kwd>множественная лекарственная резистентность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>T-cell leukemia Jurkat cells</kwd><kwd>Pgp antibody</kwd><kwd>multidrug resistance</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Widmer N. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003; 102: 3: 1142-1144.</mixed-citation><mixed-citation xml:lang="en">Widmer N. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003; 102: 3: 1142-1144.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Nagashima S. BCRP/ABCG2 levels account for the resistance to topoisomerase inhibitors and reversal effects by gefitinib in non-small-cell lung cancer. Cancer Chemother Pharmacol 2006; 58: 5: 594-600.</mixed-citation><mixed-citation xml:lang="en">Nagashima S. BCRP/ABCG2 levels account for the resistance to topoisomerase inhibitors and reversal effects by gefitinib in non-small-cell lung cancer. Cancer Chemother Pharmacol 2006; 58: 5: 594-600.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yague E., Armesilla A., Harrison G. et al. P-Glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003; 278: 12: 10344-10352.</mixed-citation><mixed-citation xml:lang="en">Yague E., Armesilla A., Harrison G. et al. P-Glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003; 278: 12: 10344-10352.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y., Yu L., Lou F. et al. The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene(mrp) and mdr-1/p170 expression in acute leukemia. Zhonghua Nei Ke Za Zhi 1999; 38: 11: 760-763.</mixed-citation><mixed-citation xml:lang="en">Zhao Y., Yu L., Lou F. et al. The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene(mrp) and mdr-1/p170 expression in acute leukemia. Zhonghua Nei Ke Za Zhi 1999; 38: 11: 760-763.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schwarzenbach H. A diagnostic tool for monitoring multidrug resistance expression in human tumor tissues. Anal Biochem 2002; 308: 1: 26-33.</mixed-citation><mixed-citation xml:lang="en">Schwarzenbach H. A diagnostic tool for monitoring multidrug resistance expression in human tumor tissues. Anal Biochem 2002; 308: 1: 26-33.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Beck W., Grogan T., Willman C. et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 13: 3010-3020.</mixed-citation><mixed-citation xml:lang="en">Beck W., Grogan T., Willman C. et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 13: 3010-3020.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H., Zhang W., Li F. Prognostic significance of MDR-1 P-glycoprotein expression in breast cancer. Journal of Nanjing Medical University 2008; 22: 3: 148-152.</mixed-citation><mixed-citation xml:lang="en">Zhang H., Zhang W., Li F. Prognostic significance of MDR-1 P-glycoprotein expression in breast cancer. Journal of Nanjing Medical University 2008; 22: 3: 148-152.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
